Lexicon Pharmaceuticals has chosen clinical trial solutions provider Medidata to help advance the Phase IIb PROGRESS study of LX9211, a non-opioid drug candidate for diabetic peripheral neuropathic pain (DPNP).
This collaboration could potentially lead to LX9211 becoming the first new drug to obtain approval for neuropathic pain in more than 20 years.
Go deeper with GlobalData
Under the deal, Medidata will aid Lexicon in expediting subject enrollment and clinical trials of the drug to enhance patient experience.
Lexicon aims to leverage Medidata’s decentralised clinical trial (DCT) solutions for this approach.
The DCT platform leverages artificial intelligence and automation for real-time remote monitoring and data capture from participants in a real-world setting, irrespective of their location in their treatment journey.
Medidata CEO Anthony Costello said: “Our innovative technology is transforming how clinical trials are initiated and managed, and ultimately improving patient experience, ensuring that new treatments can be developed and approved faster than ever before.
“We are honoured to work with Lexicon to advance this novel therapy for diabetic peripheral neuropathy with the potential to positively impact the lives of patients suffering from this condition.”
Lexicon senior vice-president and chief medical officer Craig Granowitz said: “With no new, non-opioid drugs approved for the treatment of neuropathic pain in over two decades, we are excited about the potential for LX9211.
“We are at a critical juncture in our efforts to make this medication available to diabetic patients suffering from neuropathic pain, and our partnership with Medidata has been invaluable in advancing this trial expeditiously and enrolling our first patients in the PROGRESS study.”
Recently, Medidata expanded its partnership with contract research organisation Worldwide Clinical Trials.
This collaboration is aimed at accelerating clinical trials and improving the patient experience.
